Breast cancer risk after modern radiotherapy

• Conditions: C81; C50.9; Hodgkin lymphoma; Breast, unspecified

• Registration Number: DRKS00028896
• Lead Sponsor: Medizinische Hochschule Brandenburg Campus GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-04-29
• Study Completion: 2024-06-15
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 146

Inclusion Criteria

1. Cancer diagnosed as of 2006 with upper body-directed radiotherapy treatment using any technique derived from computer tomography-based treatment planning, 2. Hodgkin, other lymphoma and sarcoma patients have top priority for admission, patients with breast cancer, lung cancer or esophageal cancer with radiotherapy radiation to the breast may be included on an individual basis, 3. all quadrants and the central area of ??both breasts can be delineated on the planning computer tomography are (or have previously been) delineated (according to the study plan below described procedure), 4. the radiotherapy dose can be determined for all quadrants (and the central area) of both breasts, 5. at least one of the breast quadrants / central areas is partially in the radiation field

Exclusion Criteria

1. patients who have received posterior radiotherapy for sarcomas, 2. patients who have received palliative radiotherapy, 3. patients less than 15 years old at the time of cancer diagnosis

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To obtain absolute breast cancer risk predictions for patients treated with modern radiotherapy plans using prediction models based on quadrant-specific doses and mean doses.

Secondary Outcome Measures

Name	Time	Method
To compare field types over time in terms of irradiated volume, prescribed dose, mean dose, and quadrant-specific doses (in combination with data on patients from previous case-control study, Krul et al 2017), and to compare relative breast cancer risks between radiotherapy plans obtained using modern and previously used techniques.